- Home
- BIOA
as 06-18-2025 4:00pm EST
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 139.8M | IPO Year: | 2024 |
| Target Price: | $5.67 | AVG Volume (30 days): | 347.3K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.88 - $26.62 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,451,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioAge Labs Inc. Common Stock News
BIOA Breaking Stock News: Dive into BIOA Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery
GlobeNewswire
a day ago
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
GlobeNewswire
15 days ago
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
TipRanks
19 days ago
BioAge Labs completes IND-enabling studies for BGE-102
Insider Monkey
20 days ago
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
GlobeNewswire
20 days ago
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
GlobeNewswire
22 days ago
BioAge Labs to Present at Upcoming Investor Conferences
GlobeNewswire
a month ago
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
Compare BIOA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIOA BioAge Labs Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.